Company: MIRA
Filing Date: 2025-08-08
Form Type: DEFM14A
Source: 0001641172-25-022816
Chunk: 51

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-08
Form: DEFM14A
Chunk 51
---
 MIRA Common Stock resulting from the announcement of the      
 Merger;                                                                                                                                |
| ● | the                                                                                                                                    
 risk that the Merger might not be consummated in a timely manner or at all and the potential adverse effect of the public announcement 
 of the Merger or delay or failure to complete the Merger on the reputation of MIRA;                                                    |
| ● | the                                                                                                                                    
 likely detrimental effect on MIRA’s cash position, stock price and ability to initiate another process and to successfully             
 complete an alternative transaction should the Merger not be completed;                                                                |
| ● | the                                                                                                                                    
 risk to MIRA’s business, operations and financial results in the event that the Merger is not consummated, including the diminution    
 of MIRA’s cash and the significant challenges associated with the need to raise additional capital through the public or private       
 sale of equity securities;                                                                                                             |
| ● | the                                                                                                                                    
 risk that the combined company could be subject to the Investment Company Act Rule 3-a2; and                                           |
| ● | various                                                                                                                                
 other risks associated with the combined company and the Merger, including those described in the section titled “Risk Factors.”       |

Neither MIRA nor the Board considered other merger candidates. MIRA’s CEO was previously familiar with SKNY and its prospects for growth and was interested in acquiring this specific company to increase shareholder value.

In view of the wide variety of reasons considered in connection with its evaluation of the Merger and the complexity of these matters, the MIRA Board did not find it useful to attempt, and did not attempt, to quantify, rank or otherwise assign relative weights to these reasons. In considering the reasons described above, individual members of the MIRA Board may have given different weight to different reasons. The MIRA Board conducted an overall analysis of the factors described above, including thorough discussions with, and questioning of, MIRA’s CEO and the legal and financial advisors of MIRA, and considered the reasons overall to be favorable to, and to support, its determination.

The LOI was signed by both MIRA and SKNY on March 19, 2025.

At no point did MIRA and SKNY enter into a non-disclosure agreement that contained any don’t ask, don’t waive standstill provisions.

On March 14, 2025, each of SKNY and MIRA granted Moore access to its data room.

On March 17, 2025, MIRA and Moore provided SKNY with a list of diligence questions related to SKNY